Abstract
Vanishing white matter (VWM) is a leukodystrophy caused by recessive variants in subunits of eIF2B. At present, no curative treatment is available and patients often die at young age. Due to its monogenic nature, VWM is a promising candidate for the development of CRISPR/Cas9-mediated gene therapy. Here we tested a dual-AAV approach in VWM mice encoding CRISPR/Cas9 and a DNA donor template to correct a pathogenic variant in Eif2b5. We performed sequencing analysis to assess gene correction rates and examined effects on the VWM phenotype, including motor behavior. Sequence analysis demonstrated that over 90% of CRISPR/Cas9-induced edits at the targeted locus are insertion or deletion (indel) mutations, rather than precise corrections from the DNA donor template by homology-directed repair. Around half of the CRISPR/Cas9-treated animals died prematurely. VWM mice showed no improvement in motor skills, weight, or neurological scores at 7 months of age, and CRISPR/Cas9-treated controls displayed an induced VWM phenotype. In conclusion, CRISPR/Cas9-induced DNA double-strand breaks (DSBs) at the Eif2b5 locus did not lead to sufficient correction of the VWM variant. Moreover, indel formation in Eif2b5 induced an exacerbated VWM phenotype. Therefore, DSB-independent strategies like base- or prime editing might better suited for VWM correction.
Original language | English |
---|---|
Pages (from-to) | 17-25 |
Number of pages | 9 |
Journal | Molecular Therapy - Methods and Clinical Development |
Volume | 25 |
Early online date | 23 Feb 2022 |
DOIs | |
Publication status | Published - 9 Jun 2022 |
Bibliographical note
Funding Information:We would like to thank Désirée Böck for the development of the plasmid to create the stably integrated Eif2b5 R191H HEK293T cell line. This work was supported by grants from the Rare Joint Call project (grant no. 9003037601 ), the Swiss National Science Foundation (grant no. 310030_185293 ), and the PHRT (grant no. 528 ).
Publisher Copyright:
© 2022 The Author(s)
Funding
We would like to thank Désirée Böck for the development of the plasmid to create the stably integrated Eif2b5 R191H HEK293T cell line. This work was supported by grants from the Rare Joint Call project (grant no. 9003037601 ), the Swiss National Science Foundation (grant no. 310030_185293 ), and the PHRT (grant no. 528 ).
Keywords
- CRISPR/Cas9
- gene editing
- gene therapy
- leukodystrophy
- vanishing white matter